Balanced against the argument, underlying the opening post, is the fact that the logistics of "fresh" content is impossible, regards MSC being pharma like in their application. Furthermore, as our CEO recently commented, there is in fact, much to be said for "off-the-shelf- [ie, frozen] treatments! Seriously, I can't see too many people wanting cell product from anyone, other than a healthy person under the age of say 25. I can't see too many folks lining up from my dodgy middle-aged cells
fresh v frozen, page-7
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |